Cantor Fitzgerald Keeps a Buy Rating on Abeona Therapeutics (ABEO)

By Ryan Adsit

In a report issued on August 10, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Abeona Therapeutics (NASDAQ: ABEO), with a price target of $36. The company’s shares closed on Friday at $13.65.

According to, Piros has 0 stars on 0-5 star ranking scale with an average return of -6.8% and a 44.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abeona Therapeutics with a $29.57 average price target, representing an 116.6% upside. In a report issued on August 10, Maxim Group also maintained a Buy rating on the stock with a $35 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $22.75 and a one-year low of $7.01. Currently, Abeona Therapeutics has an average volume of 837.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.